Every 8-K that Jade Biosciences, Inc. (JBIO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow JBIO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full JBIO filings page.
Jade Biosciences, Inc., a clinical-stage biotechnology company developing therapies for autoimmune diseases, reported results for the quarter ended June 30, 2026 and provided a pipeline update. The company highlighted positive interim Phase 1 data for JADE101 in IgA nephropathy, noting biomarker activity and durability with a favorable safety profile. JADE301, an anti-IFN-ß monoclonal antibody for dermatomyositis, is being advanced toward Phase 1 initiation, while JADE201 continues clinical progress in autoimmune diseases.
Cash, cash equivalents and investments were $461,205 thousand as of June 30, 2026, compared with $336,158 thousand at December 31, 2025. Total liabilities were $32,198 thousand and stockholders’ equity was $439,915 thousand. For the second quarter of 2026, research and development expense was $50,065 thousand and general and administrative expense was $8,851 thousand, leading to total operating expenses of $58,916 thousand versus $27,778 thousand a year earlier. Net loss for the quarter was $55,765 thousand compared with $32,134 thousand in the prior-year period, with net loss per share attributable to common stockholders of $0.76 versus $0.86.
Jade Biosciences entered a JADE301 License Agreement with Paragon Therapeutics, securing a royalty-bearing, worldwide, exclusive, sublicensable license to certain monospecific antibodies against an undisclosed target for use across all human therapeutic areas.
The company may pay Paragon up to $22.0 million in development and regulatory milestones, including a $1.5 million development candidate nomination fee paid in January 2026 and a further $2.5 million on first dosing of a human in a Phase 1 trial.
On a product-by-product basis, Jade could owe up to approximately $20.1 million in sublicensing fees, plus low to mid-single-digit royalties on annual net sales of monospecific products and mid-single-digit royalties on multispecific products, with a 30% royalty reduction where no valid patent exists and royalties lasting at least 12 years from first sale or until patent expiry.
Paragon agrees not to start new campaigns for monospecific antibodies to the same target in the field for five years, and the agreement can be terminated on 60 days’ notice, for uncured material breach, or, where allowed by law, upon a party’s insolvency or bankruptcy.
Jade Biosciences, Inc. filed an 8-K announcing that its Board appointed Mark Eisner, M.D., M.P.H., as a Class I director effective June 25, 2026. He will serve until the 2028 annual meeting and join the Nominating and Corporate Governance Committee.
Dr. Eisner brings more than 25 years of leadership in clinical development and immunology, including senior roles at Vir Biotechnology, Sonoma Biotherapeutics, FibroGen and Genentech/Roche, as well as an academic career at UCSF. In connection with his appointment, he received a stock option to purchase 47,675 shares of Jade common stock under the 2025 Stock Incentive Plan, vesting in equal monthly installments over three years and accelerating upon a change in control, subject to continued service. He will also participate in the standard non-employee director compensation program and sign the company’s standard indemnification agreement. The company issued a press release with these details.
Jade Biosciences, Inc. reported corporate governance changes following its 2026 Annual Meeting of Stockholders. Stockholders approved an amendment to the Articles of Incorporation adding a new Article X that waives jury trials in certain circumstances, which became effective when the Amended and Restated Articles were filed with the Nevada Secretary of State on June 10, 2026.
The Board also approved Amended and Restated Bylaws, effective June 9, 2026, to modernize provisions in line with the Nevada Revised Statutes. Changes include removing the requirement to prepare a pre‑meeting stockholder list, expressly permitting virtual and remote stockholder and Board meetings, clarifying how record dates apply to postponed meetings, and redefining the voting standard for most stockholder actions so that the number of votes cast in favor must exceed the number of votes cast in opposition.
At the meeting, stockholders elected Christopher Cain, Ph.D. with 34,373,784 votes for and 8,041,605 withheld, and Tom Frohlich with 42,399,190 votes for and 16,199 withheld, along with approving other proposals that received strong majorities of votes cast.
Jade Biosciences, Inc. entered into an underwriting agreement for a public offering of 10,000,000 shares of common stock at $15.00 per share, with underwriters purchasing at $14.10 per share. Jade expects gross proceeds of $150.0 million and net proceeds of approximately $140.3 million.
The company granted underwriters a 30-day option to buy up to an additional 1,500,000 shares at the public price, which would raise expected net proceeds to about $161.5 million if exercised in full. The offering, conducted under an effective Form S-3 shelf registration, is expected to close on June 5, 2026, and Jade plans to use net proceeds to fund clinical and preclinical programs, manufacturing, R&D, capital spending, working capital and general corporate purposes.
Jade Biosciences reported interim Phase 1 results for JADE101, its investigational anti‑APRIL antibody for IgA nephropathy. In 32 healthy volunteers given single subcutaneous doses from 175 mg to 1,400 mg, JADE101 showed a favorable safety profile, with only mild to moderate treatment‑emergent events and no severe adverse events or discontinuations.
A 700 mg dose produced prolonged IgA reductions of about 70% sustained at 12 weeks, with pharmacokinetic modeling suggesting this effect could be maintained using a 350 mg maintenance dose every 12 weeks. JADE101 demonstrated ultra‑high APRIL binding affinity, rapid and sustained free APRIL suppression, and an estimated half‑life of 24.2 days.
Jade has initiated JUNIPER, a Phase 2 open‑label IgA nephropathy trial in roughly 30 participants using a 700 mg induction dose followed by 350 mg maintenance every 8 or 12 weeks, with interim data anticipated in 2027. A registrational Phase 3 trial is planned for the first half of 2027, subject to FDA requirements. The company reports $311 million in cash, cash equivalents and investments as of March 31, 2026, which it expects to fund operations into the first half of 2028.
Jade Biosciences, Inc. reported first quarter 2026 financial results and highlighted progress across its autoimmune disease pipeline. The company is advancing JADE101, a selective anti-APRIL antibody for IgA nephropathy, with initial biomarker-rich Phase 1 data expected and a Phase 2 trial planned.
Additional programs include JADE201, an afucosylated anti-BAFF-R antibody, and JADE301, an undisclosed antibody candidate, both targeting autoimmune indications. For the quarter ended March 31, 2026, Jade recorded a net loss of $40,368 thousand on operating expenses of $43,445 thousand, driven mainly by $36,053 thousand in research and development spending.
Cash, cash equivalents and investments totaled $311,295 thousand as of March 31, 2026, supporting ongoing clinical development. The company’s forward-looking statements note the potential for its cash runway to extend into the first half of 2028, while emphasizing typical clinical, regulatory and funding risks.
Jade Biosciences, Inc. reported that its Board of Directors appointed Andrew King, BVMS, Ph.D. as the company’s President, Research & Development, effective April 18, 2026. Dr. King previously served as Chief Scientific Officer and Head of Research & Development, and his compensation was unchanged with this new role.
Jade Biosciences, Inc. reported that its Board of Directors approved the 2026 Employment Inducement Stock Incentive Plan. The plan is intended for new employees as an inducement to join the company, in line with Nasdaq Listing Rule 5635(c)(4).
The Board initially reserved 1,750,000 shares of common stock for awards under the plan. It is substantially similar to the company’s 2025 Stock Incentive Plan, but it does not permit incentive stock options and may only grant awards to eligible recipients under applicable Nasdaq rules.
Jade Biosciences reported fourth quarter and full year 2025 results and detailed progress across its autoimmune disease pipeline. The company ended December 31, 2025 with cash, cash equivalents and investments of $336,158 thousand and total assets of $349,781 thousand.
Total liabilities were $17,263 thousand and stockholders’ equity was $332,518 thousand, compared with a deficit a year earlier. For 2025, research and development expenses were $93,121 thousand and general and administrative expenses were $20,421 thousand, leading to a net loss of $127,410 thousand.
The net loss per share attributable to common stockholders was $3.19 basic and diluted. Management highlighted clinical momentum for JADE101 in Phase 1 for IgA nephropathy, plans to start a Phase 2 trial and first-in-human dosing of JADE201, and an expected cash runway extending into the first half of 2028.
Jade Biosciences, Inc. entered into a securities purchase agreement for a private placement of 3,214,286 shares of common stock at $14.00 per share, for expected gross proceeds of approximately $45 million before expenses. The closing is expected on December 16, 2025, subject to customary closing conditions and in accordance with applicable Nasdaq rules.
The company plans to use the net proceeds to fund research and development, as well as general corporate expenses and working capital needs, supporting ongoing operations and pipeline development.
Jade also entered into a Registration Rights Agreement with the purchaser, committing to file a registration statement (or amend an existing one) to register the resale of the shares within 45 days after closing and to seek effectiveness within 75 days, with specified penalties if these timelines are not met. The private placement relies on exemptions from registration under Section 4(a)(2) and/or Rule 506 of Regulation D, with the investor represented as an accredited investor or qualified institutional buyer and the securities sold without general solicitation.
Jade Biosciences, Inc. (JBIO) furnished its Q3 2025 results via a press release, providing an update for the quarter ended September 30, 2025. The materials were furnished, not filed, under Item 2.02.
The company also highlighted prior transaction mechanics: Aerovate completed its merger sequence with Jade on April 28, 2025, and effected a 1-for-35 reverse stock split. Historical audited financials of Pre‑Merger Jade were retroactively adjusted to the 0.6311 exchange ratio and are included as Exhibit 99.2, alongside the Q3 press release (Exhibit 99.1) and an auditor consent.
Jade Biosciences, Inc. announced securities and licensing developments related to its BAFF-R candidate, JADE201. The company agreed to issue pre-funded warrants to purchase an aggregate of 1,402,092 shares of common stock at a purchase price of $9.1399 per pre-funded warrant, where each warrant carries a $0.0001 per-share exercise price. The filing references related securities documents including a Securities Purchase Agreement dated October 6, 2025, a Form of Registration Rights Agreement and a Form of Pre-Funded Warrant.
Under a License Agreement tied to the BAFF-R program, the company paid for an IND-enabling toxicology study in April 2025 and remains obligated to a further milestone payment of $2.5 million upon the first dosing of a human patient in a Phase 1 trial. Licensed exclusivity runs to the last-to-expire relevant patent or 12 years from first commercial sale. The company published a press release and updated corporate presentation on October 7, 2025, and furnished those materials as exhibits.
Jade Biosciences, Inc. (JBIO) filed an 8-K reporting a material employment-related payment arrangement dated September 9, 2025. The filing states the company will make (i) a one-time cash payment equal to 12 months of the executive's current base salary and (ii) a cash payment equal to the COBRA premiums for continuation coverage for a period of 12 months. The disclosure is signed by Tom Frohlich, Chief Executive Officer. The filing provides the specific severance and benefits continuation terms but does not disclose the executive's name beyond the reference to Dr. Kocinsky or the dollar amounts of base salary.
Jade Biosciences, Inc. filed a current report to note that it issued a press release announcing its financial results for the quarter ended June 30, 2025. The company states that the press release, included as Exhibit 99.1, provides details of these quarterly results.
The company clarifies that the earnings press release and related disclosure are being furnished, not filed, which means they are not subject to certain liability provisions of the securities laws and are not automatically incorporated into other SEC filings.
Jade Biosciences, Inc. (NASDAQ: JBIO) filed an 8-K announcing two material events:
- Patheon Master Services Agreement (Item 1.01): On 26 June 2025 the company entered into a five-year, automatically renewable master services agreement with Patheon Biologics (Thermo Fisher). Patheon will provide cGMP development, manufacturing and testing for lead asset JADE101 and future programs on a non-exclusive, project-by-project basis. Key protections include IP assignment to Jade, notification of regulatory inspections and the right for Jade to cancel projects (subject to customary fees). Financial terms are project-specific and not disclosed, but the agreement secures commercial-scale capacity and regulatory-compliant manufacturing know-how.
- C-suite transition (Item 5.02): Bradford Dahms, age 37, will become Chief Financial Officer & Treasurer effective 14 July 2025. His compensation package comprises a $500,000 base salary, a 40 % target bonus and an option for 526,000 shares vesting over four years. Change-in-control protection provides up to 1.5× salary plus target bonus and full vesting acceleration. Mr. Dahms previously held CFO roles at IDRx, Theseus Pharmaceuticals and Selecta Biosciences, bringing deep capital-markets and business-development expertise. Incumbent SVP Finance Jonathan Quick remains with the company but relinquishes principal accounting officer duties.
Collectively, the Patheon MSA de-risks manufacturing for the clinical pipeline, while the seasoned CFO hire strengthens financial leadership ahead of potential late-stage development and capital-raising activities.